ECSP993255A - ORGANIC COMPOUNDS - Google Patents

ORGANIC COMPOUNDS

Info

Publication number
ECSP993255A
ECSP993255A ECSP993255A ECSP993255A EC SP993255 A ECSP993255 A EC SP993255A EC SP993255 A ECSP993255 A EC SP993255A EC SP993255 A ECSP993255 A EC SP993255A
Authority
EC
Ecuador
Prior art keywords
dpp
formula
organic compounds
conditions
compounds
Prior art date
Application number
Other languages
Spanish (es)
Inventor
Edwin Bernard Villhauer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority to ECSP993255 priority Critical patent/ECSP993255A/en
Publication of ECSP993255A publication Critical patent/ECSP993255A/en

Links

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a un compuesto de la fórmula I (grágico), en donde R es adamantilo sustituido; y n es de 0 a 3; en forma libre o en forma de sal de adición de ácido. Los compuestos de la fórmula I inhiben la actividad de DPP-IV(peptidiasa de dipeptidilo-IV). Por consiguiente, se indican para utilizarse como productos farmacéuticos en la inhibición de DPP-IV, y en el tratamiento de condiciones mediadas por DPP-IV, tales como diabetes mellitus no dependientes de insulina, artritis, obesidad, osteoporosis, y otras condiciones de tolerancia deteriorada a la glucosa.The present invention relates to a compound of formula I (magical), wherein R is substituted adamantyl; and n is 0 to 3; in free form or in the form of an acid addition salt. The compounds of formula I inhibit the activity of DPP-IV (dipeptidyl-IV peptidiase). Accordingly, they are indicated for use as pharmaceuticals in the inhibition of DPP-IV, and in the treatment of conditions mediated by DPP-IV, such as non-insulin dependent diabetes mellitus, arthritis, obesity, osteoporosis, and other conditions of tolerance. impaired glucose.

ECSP993255 1999-12-09 1999-12-09 ORGANIC COMPOUNDS ECSP993255A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ECSP993255 ECSP993255A (en) 1999-12-09 1999-12-09 ORGANIC COMPOUNDS

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ECSP993255 ECSP993255A (en) 1999-12-09 1999-12-09 ORGANIC COMPOUNDS

Publications (1)

Publication Number Publication Date
ECSP993255A true ECSP993255A (en) 2000-03-22

Family

ID=42044244

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP993255 ECSP993255A (en) 1999-12-09 1999-12-09 ORGANIC COMPOUNDS

Country Status (1)

Country Link
EC (1) ECSP993255A (en)

Similar Documents

Publication Publication Date Title
AR028696A1 (en) N- (REPLACED GLYCLE) -2-CYANOPIRROLIDINS
BRPI9915985B8 (en) 2-cyanopyrrolidines n-substituted, pharmaceutical composition comprising them and their use
TW200632551A (en) A salt suitable for an acid generator and a chemically amplified resist composition containing the same
PT1221444E (en) CONDENSED IMIDAZOLE DERIVATIVES AND MEDICINES FOR DIABETES MELLITUS
CL2004000969A1 (en) COMPOUNDS DERIVED FROM ALQUILARILO; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION; AND USE FOR THE TREATMENT AND / OR PROFILAXIS OF OBESITY AND RELATED DISORDERS.
BRPI0500480A (en) process for the synthesis of (1s) -4,5-dimethoxy-1- (methylaminomethyl) benzocyclobutane and its addition salts, and application to the synthesis of ivabradine and its addition salts with a pharmaceutically acceptable acid
CY1107956T1 (en) USE OF 2-AMINOTETRALINE SUBSTITUTES FOR PREVENTIVE TREATMENT OF PARKINS DISEASE
CL2004000293A1 (en) COMPOUNDS DERIVED FROM DIHYDROFENANTRIDIN-SULFONAMIDS REPLACED, ITS SALTS; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION; INTERMEDIARY COMPOUNDS; AND ITS USE IN THE TREATMENT OF TYPE II DIABETES, ALZHEIMER, SENILE DEMENTIA, ASTHMA, COL
BR9908610A (en) Compound, process to produce the same, pharmaceutical composition, use of the compound, processes to inhibit the production of nitric oxide and / or cytokine in mammals, and to prevent or treat heart disease, autoimmune disease or septic shock in mammals, and, for medications
CU23101A3 (en) 3-PROPIL GAMMA-AMINOBUTÍRICO MONO AND DISUSTITUDED ACIDS
BRPI0415203A (en) restructured pentanols, a process for their production and use as anti-inflammatory agents
DE60224276D1 (en) CANCER METASTASIS HEMMER WITH CARBACYCLIC PHOSPHATIDINE ACID DERIVATIVES
GT199900081A (en) SULFONYLBENZENE COMPOUNDS AS ANTI-INFLAMMATORY / ANALGESIC AGENTS.
BR9808854A (en) Process for preparing a compound, and, compound
ECSP993255A (en) ORGANIC COMPOUNDS
BR0318576A (en) Process for the manufacture of 1,2-benzisoxazole-3-methanesulfonamide
BR0210512A (en) (R) - (-) - 2-Hydroxy-2- (2-chlorophenyl) acetic acid decomposition process
EP1346988A4 (en) Process for preparing optically active 2,3-dihydro- benzofuran compounds
JPS5422350A (en) Purification of aromatic polyamines
DE60305003D1 (en) PROCESS FOR THE PRODUCTION OF SYNERGISTIC STABILIZER MIXTURES
NO980994L (en) Substituted phosphinic acid compounds and their use as pharmaceuticals
BR0300877A (en) Process for the preparation of cyclic diketones
BR0107898A (en) Process for the preparation of the compound, compound, pharmaceutical composition, use of the compounds, and, process for the preparation of the compounds
MXPA05008190A (en) Oligosaccharide derivative.
FI821038A0 (en) MORFOLINER